DETECTION OF A RARE MUTATION IN A NOONAN SYNDROME SUSPECTED PATIENT: A CASE REPORT by Boban Dobrevski et al.
 
 Dobrevski B 
DOI: 10.33602/mebm.3.1.7 




DETECTION OF A RARE MUTATION IN A NOONAN SYNDROME 
SUSPECTED PATIENT: A CASE REPORT 
Boban Dobrevski
1















Abstract: Noonan syndrome (NS) is a genetic autosomal dominant condition, caused by mutations in PTPN11 and 
other genes. The aim of this report is to highlight a finding of a rare mutation in the RAF1 gene in a six-year-old child 
evaluated for Noonan Syndrome. An Ampliseq Research Panel covering A2ML1, BRAF, CBL, HRAS, KRAS, 
MAP2K1, MAP2K2, NRAS, PTPN11, RAF1, RIT1, SHOC2, SOS1 and SPRED1 genes was used on the Ion Torrent 
platform. Out of 54 variants detected, a single nucleotide missense mutation c.483T>G in the RAF1 gene was classified 
as likely pathogenic, based on a single previous submission to Clinvar. Further investigations may shed light on the 
possible role of this variant in the pathogenesis of Noonan Syndrome and other RASopathies. 
 
1
Institute of Immunobiology and Human Genetics, 
Faculty of Medicine, “Ss. Cyril and Methodius” 
University of Skopje, Republic of North Macedonia 
2
University Clinic for Pediatric Diseases, Skopje, 



























Institute of Immunobiology and Human Genetics, Faculty of 
Medicine, “Ss. Cyril and Methodius” University of Skopje, Republic 






Submitted: March, 2020 









Noonan syndrome (NS) is an autosomal dominant 
condition with high phenotypic variability.
1
 It is a 
clinically and genetically heterogeneous disorder that 
belongs to the group of RASopathy diseases, caused by 
mutations in genes regulating the RAS/MAPK 
pathway.
2
 The incidence of this syndrome is 
approximately 1 in 1000 to 2500 people.
1
 
NS was first described as a separate entity in 1963 by 
Dr. Jacqueline Noonan, who reported nine patients 
with pulmonary valve stenosis, small stature, 
hypertelorism, mild intellectual disability, ptosis, 
undescended testes and skeletal malformations.
3
 Years 
after her publication, the understanding of the genetic 
causes of Noonan syndrome has increased immensely, 
enabling the study of the complex pathophysiological 
mechanisms leading to this disorder. 
The RAS/mitogen-activated protein kinase (MAPK) 
pathway plays a fundamental role in the regulation of 
the cell cycle, differentiation, growth and cell 
senescence. Consequently, its dysregulation has serious 
effects on development as seen in different 
RASopathies. These conditions all have similar signs 
and symptoms and are caused by changes in the same 
cell signaling pathway. In addition to Noonan 
syndrome, the RASopathies include 
cardiofaciocutaneous syndrome (CFC), Costello 
syndrome, neurofibromatosis type 1, Legius syndrome, 
and Noonan syndrome with multiple lentigines. The 
numerous overlapping characteristics make it 




NS is caused by gene mutations that result in increased 
signal transduction down the RAS/MAPK pathway. 
Suspicion for NS is often raised after birth, on the basis 
of distinctive facial and musculoskeletal features. 
However, a few prenatal findings may also be 
observed: polyhydramnios, lymphatic dysplasia 
including increased nuchal translucency and cystic 
hygroma, relative macrocephaly, cardiac, and renal 
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 The facial dysmorphology is more 
remarkable in infancy and early childhood and 
becomes more subtle with age.
6
 Newborns with NS 
have a large head with a small face, a tall forehead 
narrowing at the temples. The eyes are wide-spaced 
with epicanthal folds, ptosis and horizontal or down-
slanting palpebral fissures. They are usually pale blue 
or blue-green in color. Telecanthus and hypertelorism 
is also observed. The nose is short and broad. The ears 
are low-set and posteriorly rotated. The upper lip is 
noticeable with a deeply grooved philtrum and full lips. 
Affected individuals may have a high arched palate and 
micrognathia. Commonly, patients with NS have a 
short neck with excess skin, called webbing, and a low 
posterior hairline. In toddlers, the hair is wispy, 
whereas it is often curly or wooly in older children.
2
 
Birth weight and length are usually normal, but there is 
a subsequent decline in height and weight with age. 
More than half of individuals with NS have a short 
stature. Abnormal levels of growth hormone may be a 
contributor to the slow growth.
7
 Delayed puberty is 
also observed.
8
 Most males with NS have 
cryptochidism.
9
 A characteristic feature in NS patients 
are chest deformities such as pectus carinatum and 
pectus excavatum. Abnormal pigmentation of the skin 
can be noticed, including café au lait spots, pigmented 
naevi and lentigenes. Noonan syndrome is the second 
most common syndromic cause of congenital heart 
disease (CHD), exceeded in prevalence only by trisomy 
21. Pulmonary stenosis (PS), often with dysplastic 
valves, is the most common finding in NS patients (50-
60%), followed by hypertrophic cardiomyopathy (20%) 
and secundum atrial septal defect (ASD) (6-10%). 
Other heart abnormalities are also noted.
1
 Individuals 
with NS quite often have a bleeding diathesis (30-
65%), although the symptoms are mostly mild.
10
 
Knowing the importance of the RAS/MAPK pathway 
in cell cycle regulation, it is not surprising that 
individuals with NS have an eightfold greater risk of 
developing childhood cancer than those without NS.
11
 
The neurologic, cognitive and behavioral side of NS is 
still poorly understood, but most children diagnosed 
with NS have normal intelligence. Few need special 
education and some have intellectual disability.
2
 
Noonan syndrome is diagnosed on a clinical basis by 
its distinctive phenotypic features, but, as mentioned 
before, the great number of shared characteristics 
makes it difficult to distinguish it from other 
RASopathies.
4
 Advancements in the field of 
comprehensive molecular testing such as NGS (Next 
Generation Sequencing) help in the identification and 
confirmation of NS suspected patients.
12
 Pathogenic 
variants in the PTPN11 gene are found in 50% of NS 
individuals, variants in the SOS1 gene in 
approximately 13%, RAF1 and RIT1 are each 
implicated in 5% and KRAS in fewer than 5% of 
patients. Other reported genes in which pathogenic 
variants have been found to cause NS in less than 1% 
of cases, include: BRAF, LZTR1, MAP2K1, and NRAS. 
Several additional genes associated with a Noonan-
syndrome-like phenotype in fewer than ten individuals 
worldwide have been identified. 
CASE 
We present a case of a 6 years old girl suspected for 
Noonan syndrome. The first encounter with the patient 
was 4 years ago. She was sent to the University Clinic 
for Pediatric Diseases in Skopje for dysmorphological 
assessment after a surgical procedure for ASD. After a 
detailed anamnesis, the following information was 
gathered: a suspicious prenatal heart murmur was noted 
via Doppler sonography in the second trimester of 
pregnancy, polyhydramnios was observed in late third 
trimester, delivery was made by a Cesarean section as a 
first child in the family. Examination showed 
distinctive dysmorphological features such as curly and 
wispy hair, tall and wide forehead, wide-spaced eyes 
with epicanthal folds, low-set and posteriorly rotated 
ears with anoval thick helix, deeply grooved philtrum 
and full lips, puffy hands and deep dermatoglyphs. 
Karyotyping was ordered, and it showed normal female 
karyotype (46,XX). The clinical findings of the child 
pointed to Noonan or CFC syndrome. At that time 
genetic testing was not done. The patient was 
monitored by pediatricians and a psychologist every six 
months for the following two years. During physical 
exams, chest deformity was observed (a characteristic 
NS feature
1
), which, combined with previous findings, 
resulted in obtaining NS diagnosis. During that period 
there were admissions to the Nephrology Clinic due to 
a grade 2 left kidney hydronephrosis and, most 
recently, to the Surgery Department for a surgical 




MATERIAL AND METHODS 
A DNA sample was obtained using salting out method 
from patient’s whole blood, and was sent to the genetic 
laboratory at the Institute of Immunobiology and 
Human Genetics, Faculty of Medicine, Ss. Cyril and 
Methodius University in Skopje. The DNA 
concentration was adjusted to 20 ng/L using the Qubit 
system. The Ion Ampliseq Noonan Research Panel 
covering 14 genes known to be related with this 
disorder was used. The panel assesses A2ML1, BRAF, 
CBL, HRAS, KRAS, MAP2K1, MAP2K2, NRAS, 
PTPN11, RAF1, RIT1, SHOC2, SOS1 and SPRED1 
genes. An automated preparation of library and 
templating was done using the Ion Chef system. Panel 
sequencing was performed on the Ion GeneStudio S5 





Analysis of the sample resulted in identifying 54 
variants. The number of exonic and intronic variants 
identified per gene is displayed in Table 1. 
When searching ClinVar, 11 of the intronic variants 
were classified as benign, 2 as likely benign and 23 
have not been submitted. Evaluation of exonic variants, 
according to ClinVar, revealed 17 benign variants and 
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1 single nucleotide variant, missense mutation in RAF1 
gene c.483T>G (p.Asn161Lys) classified as likely 




Table 1. Number of exonic and intronic variants identified per 
gene  
Gene Exonic variants Intronic variants 
NRAS 1 1 
RIT1 1 4 
SOS1 / 8 
RAF1 1 1 
BRAF / 1 
SHOC2 / 1 
HRAS1 1 1 
CBL / 2 
A2ML1 9 8 
KRAS 1 1 
SPRED1 2 5 
MAP2K1 / 2 




Out of the total 54 variants identified with the Noonan 
Sydrome Ampliseq panel, none of them were directly 
associated with this disorder. The most notable change 
was found in the RAF1 gene. This exonic variant 
c.483T>G leading to amino acid change 
(p.Asn161Lys) was classified as likely pathogenic in 
the ClinVar database based on one submission from 
GeneDx on 29
th
 January 2019, after fulfilling 
GeneDx’s Variant Classification criteria. However, no 
information on the phenotypic and/or clinical 
significance of this variant is available. The mutation 
results in N161K protein change. N161K was not 
observed in approximately 6500 individuals of 
European and African American ancestry in the 
NHLBI Exome Sequencing Project, indicating it is not 
a common variant in these populations. The N161K 
variant is a semi-conservative amino acid substitution, 
resulting in possible change of secondary protein 
structure. Several in silico prediction tests are 
incorporated in the Ion Torrent software, and they 
agree in predictions of harmfulness of the predicted 
variant protein structure and function. For example, a 
SIFT algorithm and score predicts how much an amino 
acid substitution affects protein function. The SIFT 
score ranges from 0.0 (deleterious) to 1.0 (tolerated). 
Variants with scores closer to 0.0 are more confidently 
predicted as deleterious. The calculated SIFT score for 
the N161K change was 0.0.
13
 The PolyPhen-2 score 
represents the probability that a substitution is 
damaging. With the calculated value of 0.607, this 
variant is possibly damaging.
14
 Lastly, the Functional 
Analysis through Hidden Markov Models (FATHMM) 
score of 0.9 for coding variants is significantly 
associated with pathogenic variants.
15
 Having these 
predictions in mind, the variant is classified as likely 
pathogenic. 
There are more than 20 defined RAF1 mutations 
causing Noonan Syndrome. The RAF1 gene codes the 
synthesis of a protein that is part of the RAS/MAPK 
signaling pathway, which transmits chemical signals 
from outside the cell to the cell's nucleus. RAS/MAPK 
signaling helps control the cells proliferation, 
differentiation, migration and apoptosis. The RAF1 
gene mutations change single amino acids in the RAF1 
protein. Those changes disrupt the regulation of the 
RAS/MAPK signaling pathway by increased protein 
activity. It is believed that this disruption in normal cell 
processes plays a role in the development of signs and 
symptoms of Noonan syndrome, with an accent on 
cardiac defects. 
In conclusion, we report a rare, likely pathogenic RAF1 
gene variant discovered in our patient using the 
Noonan AmpliSeq Panel, with unconfirmed clinical 
significance. Further investigation of the variant and, if 
possible, analysis of the parents, could help with the 
clarification of the impact on protein function and, 
hopefully, in identifying new pathogenic variants 
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